NASDAQ$RLMD
Relmada Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Relmada reported fourth quarter and full-year 2022 financial results and provided a corporate update.
Relmada Therapeutics reported their Q4 and full-year 2022 financial results, focusing on the analysis of Reliance I (Study 301) data and plans for further development of REL-1017 as an adjunctive treatment for major depressive disorder (MDD). They intend to implement changes to Reliance II (Study 302) and initiate a new trial, Study 304, with sufficient funding to execute these plans.
- Analysis of Reliance I (Study 301) data identified key issues.
- Focus on further development of REL-1017 as an adjunctive treatment for MDD.
- Critical changes to Reliance II (Study 302) will be implemented, and a new trial, Study 304, will be initiated.
- Relmada is sufficiently funded to fully execute the plans for the further development of REL-1017 with Study 302 and Study 304.
Headline financials
Revenue & EPS history
Relmada · Revenue · Quarterly
-$9.87K
Forward guidance
Relmada Therapeutics is focusing on clinical trial execution to gain approval for REL-1017, having identified key issues from Study 301 and planning to implement changes in ongoing and new trials.
Tailwinds
- Identified the most reliable sites for trials.
- Identified the most suitable patients for trials.
- Improved study protocols.
- All other pre- and clinical, and CMC pieces are in place for a successful NDA filing for REL-1017.
- Sufficiently funded to fully execute plans for further development of REL-1017
Headwinds
- Potential failure of Reliance trial results to demonstrate clinically significant evidence of efficacy and/or safety
- Failure of top-line results to accurately reflect the complete results of the trial
- Failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder
- Risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements
- Not possible to predict or identify all the risks, uncertainties and other factors that may affect future results
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
-1.6%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+3.2%
Avg return
30 days after
35%
15 / 43 earnings
Positive
+10.8%
Q4 2024
Best reaction
-29.0%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -12.5% | — | |
| Q1 2026 | +1.2% | -6.1% | -11.4% | |
| Q3 2025 | +1.8% | +7.7% | +4.6% | |
| Q2 2025 | -2.5% | -5.6% | +174.1% | |
| Q1 2025 | +6.6% | +33.4% | +53.6% | |
| Q4 2024 | +10.8% | -5.1% | +33.2% | |
| Q3 2024 | -3.5% | -2.9% | -86.5% | |
| Q2 2024 | -29.0% | -29.0% | -25.9% | |
| Q1 2024 | -0.5% | -7.6% | -22.8% | |
| Q4 2023 | -19.6% | -12.0% | -22.1% | |
| Q3 2023 | -2.0% | -7.5% | -16.1% | |
| Q2 2023 | +3.0% | +17.4% | +34.5% | |
| Q1 2023 | -9.2% | -10.7% | -19.0% | |
| Q4 2022 | -3.0% | +4.3% | +12.8% | |
| Q3 2022 | +10.4% | +2.3% | -53.5% | |
| Q2 2022 | -0.7% | -2.8% | +8.9% | |
| Q1 2022 | -12.4% | -18.5% | -20.1% | |
| Q4 2021 | +7.5% | +10.4% | +4.9% | |
| Q3 2021 | -8.2% | -12.0% | -24.4% | |
| Q2 2021 | +4.8% | +0.6% | +13.6% | |
| Q1 2021 | -4.1% | +0.0% | -10.9% | |
| Q4 2020 | -10.4% | -7.4% | +4.3% | |
| Q3 2020 | +0.0% | +8.3% | +0.9% | |
| Q2 2020 | -0.3% | +7.7% | +0.0% | |
| Q1 2020 | +9.6% | +8.5% | +12.6% | |
| Q4 2019 | -0.1% | -1.7% | +19.7% | |
| Q3 2019 | -3.0% | -5.1% | +29.9% | |
| Q2 2019 | -4.0% | -8.5% | +106.8% | |
| Q1 2019 | +0.0% | +1.7% | +13.9% | |
| Q3 2018 | +5.1% | +2.6% | -1.7% | |
| Q1 2018 | -5.0% | +5.3% | -13.3% | |
| Q2 2018 | +0.0% | -2.1% | -3.5% | |
| Q4 2017 | +4.7% | +4.7% | -11.0% | |
| Q3 2017 | -2.0% | -2.0% | -20.6% | |
| Q2 2017 | -8.6% | -4.8% | -32.9% | |
| Q1 2017 | +7.4% | +0.0% | -19.3% | |
| Q3 2016 | -17.8% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -1.1% | — | — | |
| Q3 2015 | -2.5% | — | — | |
| Q2 2014 | +4.2% | — | — | |
| Q3 2014 | -4.6% | — | — | |
| Q1 2015 | +5.9% | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro